Skip to main content
. Author manuscript; available in PMC: 2013 Jan 19.
Published in final edited form as: N Engl J Med. 2011 Jun 5;364(26):2507–2516. doi: 10.1056/NEJMoa1103782

Figure 1. Overall Survival.

Figure 1

Panel A shows Kaplan–Meier estimates of survival in patients in the intention-to-treat population. Patients could be evaluated for overall survival if they had undergone randomization at least 2 weeks before the clinical cutoff date. An inadequate number of patients were evaluated after 7 months of follow-up in either study group to provide reliable Kaplan–Meier estimates of the survival curves. The vertical lines indicate that patients’ data were censored. Panel B shows hazard ratios and 95% confidence intervals (CI) for rates of overall survival in prespecified subgroups of patients, according to various baseline characteristics. In both panels, data are shown for patients who received no study treatment (48 patients in the dacarbazine group and 2 patients in the vemurafenib group) and for 1 patient who was assigned to the dacarbazine group but who received vemurafenib. NR denotes not reached.